Antibodies still good after 6 months in patients with end-stage kidney disease

With each passing day, worries of fading antibodies are fading. The further we get from the initial outbreak and from the vaccine rollout, the more confident we can become about antibody levels staying above detectable and protective thresholds. 

One thing we are monitoring closely, however, is how patients with high risk for severe covid-19 are progressing. For example, if antibody levels lag among patients older than 75, that would be a concern, as this is the age group with the highest documented rates of severe illness and deaths. Another group that we are worried about is end-stage kidney disease patients who require dialysis. Fortunately, a new study in Annals of Internal Medicine provides encouraging news. 

Researchers tracked antibody levels over time in dialysis-dependent patients who had recovered from covid-19. As in other studies, the antibody levels in the blood fell a bit over time, but on average a small amount. Based on this, and the low number of repeat covid-19 cases in this group (and others), the authors believe that antibodies created in response to natural infection are holding up well. In fact, of the 2,063 covid-19-recovered patients who had detectable antibody levels at the start of the study, only 6.6 percent did not have measurable levels six months later. Whether that minority of patients is at risk of a repeat infection is unclear, as other measures of the immune system were not included in this study. The good news is that patients with diabetes were less likely to have undetectable antibody levels. That's important because diabetes is known to be one of the stronger predictors of serious covid-19 illness. In addition, the slow tapering off of antibody levels was not correlated to age, sex, or race/ethnicity. Finally, a report in which demographics do not appear to have had a major impact on the outcome.


Vaccination uncertainty for people with compromised immune systems complicates return to normal

From the earliest days of the covid-19 pandemic, the goals of vaccine production have been to reach "herd immunity" by getting as many shots in as many arms as possible to limit the pool of available hosts for the virus to use. The vaccine-hesitant were going to always prove to be a challenge, but one community that has gotten short shrift is those who are, for one reason or another, immunocompromised

By design, this group of people was excluded from the clinical trials of the major vaccine candidates, and as a result, very little is known about how their bodies respond to the various available coronavirus inoculations. Absent a national or transnational coordinated effort, the studies on these individuals have been anecdotal, local, and unfortunately conflicting. Part of the issue is that there are so many different types of afflictions, be it bone and blood cancers, immunosuppression after organ transplant or for chronic conditions, or a variety of advanced illnesses, and there is no clear information on what sort of protection is provided by vaccination.

As the country is opening up and masking mandates are falling off, people who are immunocompromised are finding themselves increasingly in a world where they may still be at risk of exposure, but now without the added protections of social distancing and personal protective equipment use. 

Further complicating the picture is recent data from the US Centers for Disease Control and Prevention (CDC) weekly update showing a significant disparity in vaccination rates between rural and urban communities, as we covered yesterday in Brief19. In effect, this is creating areas of the country where, through no fault of their own, it is unsafe for the immunocompromised to travel or even participate in some daily activities that "the rest of us" are now beginning to resume. 

The intent of public health measures is to protect everyone, with small actions from individuals amounting to significant changes in safety for the masses. But if the majority of individuals are moving on to a post-pandemic mentality, how do we continue to protect our most vulnerable? Right now, there is no good answer. Various.

  • Rural vaccination numbers far lower than urban peers in US
  • Over 100 million Johnson & Johnson doses on hold for inspection